continued

Hikma has strong start to 2024, with continued momentum across all businesses. Full year guidance reiterated

Hikma has strong start to 2024, with continued momentum across all businesses. Full year guidance reiterated

Hikma has strong start to 2024, with continued momentum across all businesses. Full year guidance reiterated

AETOSWire April 25, 2024

Amman, Jordan Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on current...

Anghami Reports 35.6% Revenue Growth in Preliminary Unaudited 2022 Results, with Focus on Continued Efficiency and Profitability for 2023

Anghami Reports 35.6% Revenue Growth in Preliminary Unaudited 2022 Results, with Focus on Continued Efficiency and Profitability for 2023

Anghami Reports 35.6% Revenue Growth in Preliminary Unaudited 2022 Results, with Focus on Continued Efficiency and Profitability for 2023

AETOSWire March 8, 2023

Abu Dhabi, United Arab Emirates — Anghami Inc. (NASDAQ: ANGH), the leading streaming platform for music and...

Hikma continued strategic progress and updated full-year guidance following Custopharm acquisition

Hikma continued strategic progress and updated full-year guidance following Custopharm acquisition

Hikma continued strategic progress and updated full-year guidance following Custopharm acquisition

AETOSWire April 29, 2022

London, England – Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on...